1-sided p-value evaluated at 2.5% level for superiority 14.4 Safety Outcomes Trial DEVOTE (NCT01959529) Cardiovascular Outcomes Trial of TRESIBA Administered Once-Daily Between Dinner and Bedtime in Combination with Standard of Care in Subjects with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease DEVOTE was a multi-center, multi-national, randomized, double-blinded, active-controlled, treat-to-target, event-driven trial
Cagrilintide is a long-acting amylin analogue administered once weekly by subcutaneous injection, reducing appetite by slowing gastric emptying and suppressing glucagon
Key Takeaway: Research-grade GHK-Cu is verified by reversed-phase HPLC (purity) and LC-MS (identity), with full documentation provided on a certificate of analysis
Sharma, R., Harlev, A., Agarwal, A
A blood glucose level of 54 mg/dL or less was reported in 26% of patients receiving the 7 mg tablets, 30% of patients receiving the 14 mg tablets, and 32% with placebo
For Nordstrom, the B.C
